Candidate: Monoclonal antibodies to prevent COVID-19 disease.
Type: Coronavirus-neutralizing antibodies developed through the company’s program to use the Defense Advances Research Project Agency’s Pandemic Prevention Platform (P3).
Status: The Biomedical Advanced Research and Development Authority (BARDA) said June 9 it will award AstraZeneca $23.65 million and join the Defense Advanced Research Projects Agency (DARPA) within the Department of Defense in partnering with the company to advance its monoclonal antibody combination therapy for the treatment and protection against COVID-19 into Phase I clinical development.
The agencies will also work with AstraZeneca to manufacture the antibodies for Phase I testing. AstraZeneca reasons that a combination of monoclonal antibodies that neutralizes the SARS-CoV-2 virus could both prevent and treat COVID-19 infections.
In April, AstraZeneca said it is exploring three potential sources for antibodies against SARS CoV-2: Patients who have recovered from COVID-19, immunized humanized mice, and lab techniques such as phage display: “AstraZeneca is aiming for clinical evaluation in the next 3 to 5 months.”
AstraZeneca also disclosed collaborations with external partners: The Chinese Academy of Sciences, and Vanderbilt University Medical Center have provided genetic sequences for antibodies they have discovered against SARS2-CoV-2 for further in silico and in vitro assessment, while the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) and the University of Maryland School of Medicine are conducting preclinical safety and efficacy assessments of antibody candidates discovered through internal research.
The company said March 24 it will donate 9 million face masks for healthcare workers worldwide, with Italy receiving the first shipments.
COVID-19: 200 Candidates and Counting
To navigate through the >200 potential therapeutic and vaccine options for COVID-19, GEN has grouped the candidates into four broad categories based on their developmental and (where applicable) clinical progress:
● FRONT RUNNER – the most promising therapeutics/vaccines based on clinical progress, favorable data or both.
● DEFINITELY MAYBE – earlier phases with promising partners, or more advanced candidates in development that have generated uneven data
● KEEPING AN EYE ON… – interesting technology, attracting notable partners, or both, but preliminary data.
● TOO SOON TO TELL – longshots pending additional experimental and/or clinical data.
GEN has also tagged the most common treatment types: